Publications from OUS - Metastasis Biology and Experimental Therapeutics (Mælandsmo)

386 publications found

Publications 2024

1. Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
   Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
   World J Urol, 42 (1), 95
   DOI 10.1007/s00345-024-04787-8, PubMed 38386171
2. Valsalakumari R, Pandya AD, Prasmickaite L, Kvalvaag A, Myrann AG, Åslund AKO, Kjos MS, Fontecha-Cuenca C, Haroon HB, Ribeiro ARS, Horejs-Hoeck J, Moghimi SM, Mørch Ý, Skotland T, Sandvig K, Mælandsmo GM, Iversen TG (2024)
   Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
   Int J Nanomedicine, 19, 3009-3029
   DOI 10.2147/IJN.S450283, PubMed 38562610

Publications 2023

1. Ghannoum S, Fantini D, Zahoor M, Reiterer V, Phuyal S, Leoncio Netto W, Sørensen Ø, Iyer A, Sengupta D, Prasmickaite L, Mælandsmo GM, Köhn-Luque A, Farhan H (2023)
   A combined experimental-computational approach uncovers a role for the Golgi matrix protein Giantin in breast cancer progression
   PLoS Comput Biol, 19 (4), e1010995
   DOI 10.1371/journal.pcbi.1010995, PubMed 37068117
2. Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
   Liver X receptors induce antiproliferative effects in basal-like breast cancer
   Mol Oncol, 17 (10), 2041-2055
   DOI 10.1002/1878-0261.13476, PubMed 37341140
3. Knutsen E, Das Sajib S, Fiskaa T, Lorens J, Gudjonsson T, Mælandsmo GM, Johansen SD, Seternes OM, Perander M (2023)
   Identification of a core EMT signature that separates basal-like breast cancers into partial- and post-EMT subtypes
   Front Oncol, 13, 1249895
   DOI 10.3389/fonc.2023.1249895, PubMed 38111531
4. Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
   MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
   Cancers (Basel), 15 (18)
   DOI 10.3390/cancers15184662, PubMed 37760629
5. Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
   High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
   PLoS One, 18 (1), e0280507
   DOI 10.1371/journal.pone.0280507, PubMed 36706086
6. Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
   The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
   Sci Rep, 13 (1), 7339
   DOI 10.1038/s41598-023-34087-x, PubMed 37147361
7. Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
   Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
   Sci Rep, 13 (1), 9186
   DOI 10.1038/s41598-023-36328-5, PubMed 37280349
8. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
   A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
   Cancer Res Commun, 3 (2), 235-244
   DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
9. Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L (2023)
   Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
   Front Oncol, 13, 1040665
   DOI 10.3389/fonc.2023.1040665, PubMed 36910663

Publications 2022

1. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
   ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
   JCO Precis Oncol, 6 (1), e2200015
   DOI 10.1200/PO.22.00015, PubMed 35476549
2. Fiorito E, Szybowska P, Haugsten EM, Kostas M, Øy GF, Wiedlocha A, Singh S, Nakken S, Mælandsmo GM, Fletcher JA, Meza-Zepeda LA, Wesche J (2022)
   Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
   Br J Cancer, 127 (11), 1939-1953
   DOI 10.1038/s41416-022-01973-6, PubMed 36097178
3. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
   Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
   J Control Release, 349, 1
   DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
4. Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
   Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
   Eur Urol Open Sci, 45, 68-75
   DOI 10.1016/j.euros.2022.09.002, PubMed 36353660
5. Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
   Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
   Cancers (Basel), 14 (5)
   DOI 10.3390/cancers14051326, PubMed 35267636
6. Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022)
   miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
   Breast Cancer (Dove Med Press), 14, 25-39
   DOI 10.2147/BCTT.S338404, PubMed 35256859
7. Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
   Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
   Pathol Res Pract, 241, 154243
   DOI 10.1016/j.prp.2022.154243, PubMed 36481650
8. Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R (2022)
   Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
   Front Oncol, 12, 873516
   DOI 10.3389/fonc.2022.873516, PubMed 35692804
9. Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
   AXL inhibition improves BRAF-targeted treatment in melanoma
   Sci Rep, 12 (1), 5076
   DOI 10.1038/s41598-022-09078-z, PubMed 35332208
10. Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
    Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
    Acta Oncol, 61 (8), 955-962
    DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
11. Sivanesan S, Taskén KA, Grytli HH (2022)
    Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
    JAMA Netw Open, 5 (1), e2145230
    DOI 10.1001/jamanetworkopen.2021.45230, PubMed 35080602
12. Tellez-Gabriel M, Tekpli X, Reine TM, Hegge B, Nielsen SR, Chen M, Moi L, Normann LS, Busund LR, Calin GA, Mælandsmo GM, Perander M, Theocharis AD, Kolset SO, Knutsen E (2022)
    Serglycin Is Involved in TGF-β Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue
    Front Oncol, 12, 868868
    DOI 10.3389/fonc.2022.868868, PubMed 35494005

Publications 2021

1. Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L (2021)
   Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
   Mol Oncol, 15 (8), 2026-2045
   DOI 10.1002/1878-0261.12951, PubMed 33759347
2. Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
   Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
   Front Oncol, 11, 671629
   DOI 10.3389/fonc.2021.671629, PubMed 34178659
3. Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A (2021)
   RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
   Nat Commun, 12 (1), 6427
   DOI 10.1038/s41467-021-26018-z, PubMed 34741021
4. Erdélyi K, Ditrói T, Johansson HJ, Czikora Á, Balog N, Silwal-Pandit L, Ida T, Olasz J, Hajdú D, Mátrai Z, Csuka O, Uchida K, Tóvári J, Engebraten O, Akaike T, Børresen Dale AL, Kásler M, Lehtiö J, Nagy P (2021)
   Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
   Proc Natl Acad Sci U S A, 118 (45)
   DOI 10.1073/pnas.2100050118, PubMed 34737229
5. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
   Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
   Sci Rep, 11 (1), 6731
   DOI 10.1038/s41598-021-86239-6, PubMed 33762676
6. Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
   Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
   J Pers Med, 11 (7)
   DOI 10.3390/jpm11070605, PubMed 34206815
7. Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
   Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
   JCO Precis Oncol, 5
   DOI 10.1200/PO.20.00086, PubMed 34036235
8. Hovda T, Hoff SR, Larsen M, Romundstad L, Sahlberg KK, Hofvind S (2021)
   True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms
   Acad Radiol, 29 Suppl 1, S180-S191
   DOI 10.1016/j.acra.2021.03.022, PubMed 33926794
9. Karvelsson ST, Sigurdsson A, Seip K, Grinde MT, Wang Q, Johannsson F, Mælandsmo GM, Moestue SA, Rolfsson O, Halldorsson S (2021)
   EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition
   Mol Cancer Res, 19 (9), 1546-1558
   DOI 10.1158/1541-7786.MCR-20-0962, PubMed 34088869
10. Karvelsson ST, Wang Q, Hilmarsdottir B, Sigurdsson A, Moestue SA, Mælandsmo GM, Halldorsson S, Gudmundsson S, Rolfsson O (2021)
    Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer
    NPJ Syst Biol Appl, 7 (1), 36
    DOI 10.1038/s41540-021-00195-5, PubMed 34535676
11. Krzyscik MA, Zakrzewska M, Sørensen V, Øy GF, Brunheim S, Haugsten EM, Mælandsmo GM, Wiedlocha A, Otlewski J (2021)
    Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
    Biomacromolecules, 22 (10), 4169-4180
    DOI 10.1021/acs.biomac.1c00662, PubMed 34542998
12. Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
    MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
    Sci Rep, 11 (1), 10893
    DOI 10.1038/s41598-021-90385-2, PubMed 34035375
13. Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, Maelandsmo GM, Fodstad Ø, Pulido R, López JI (2021)
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
    Prostate, 81 (12), 838-848
    DOI 10.1002/pros.24180, PubMed 34125445
14. Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
    Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
    Sci Rep, 11 (1), 6317
    DOI 10.1038/s41598-021-85613-8, PubMed 33737576
15. Pandya AD, Iversen TG, Moestue S, Grinde MT, Mørch Ý, Snipstad S, Åslund AKO, Øy GF, Kildal W, Engebråten O, Sandvig K, Skotland T, Mælandsmo GM (2021)
    Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
    Nanomaterials (Basel), 11 (5)
    DOI 10.3390/nano11051140, PubMed 33924869
16. Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
    Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
    Carcinogenesis, 42 (5), 685-693
    DOI 10.1093/carcin/bgab015, PubMed 33609362
17. Svendsen HA, Meling TR, Nygaard V, Waagene S, Russnes H, Juell S, Rogne SG, Pahnke J, Helseth E, Fodstad Ø, Maelandsmo GM (2021)
    Novel human melanoma brain metastasis models in athymic nude fox1^nu mice: Site-specific metastasis patterns reflecting their clinical origin
    Cancer Med, 10 (23), 8604-8613
    DOI 10.1002/cam4.4334, PubMed 34612023
18. Tamhane T, Njenga RW, Burden RE, Bueth H, Maelandsmo GM, Haugen MH, Scott CJ, Brix K (2021)
    Trafficking of Full-Length and N-Terminally Truncated Cathepsin B in Human Colorectal Carcinoma Cells
    Appl. Sci.-Basel, 11 (24), 11936
    DOI 10.3390/app112411936
19. Valsalakumari R, Yadava SK, Szwed M, Pandya AD, Mælandsmo GM, Torgersen ML, Iversen TG, Skotland T, Sandvig K, Giri J (2021)
    Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
    Int J Pharm, 597, 120217
    DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035
20. van der Zanden TM, Mooij MG, Vet NJ, Neubert A, Rascher W, Lagler FB, Male C, Grytli H, Halvorsen T, de Hoog M, de Wildt SN (2021)
    Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework
    Clin Pharmacol Ther, 110 (4), 952-965
    DOI 10.1002/cpt.2336, PubMed 34145575

Publications 2020

1. Barkovskaya A, Seip K, Prasmickaite L, Mills IG, Moestue SA, Itkonen HM (2020)
   Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells
   Sci Rep, 10 (1), 16992
   DOI 10.1038/s41598-020-74083-z, PubMed 33046784
2. Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
   Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
   Mol Ther, 29 (3), 1199-1213
   DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
3. Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
   Soluble AXL as a marker of disease progression and survival in melanoma
   PLoS One, 15 (1), e0227187
   DOI 10.1371/journal.pone.0227187, PubMed 31917795
4. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
   Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
   Transl Oncol, 13 (8), 100793
   DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
5. Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
   Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
   Eur Urol Open Sci, 21, 51-60
   DOI 10.1016/j.euros.2020.08.007, PubMed 34337468
6. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
   Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
   Front Oncol, 10, 590755
   DOI 10.3389/fonc.2020.590755, PubMed 33324562
7. Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS, Oslo Breast Cancer Research Consortium (OSBREAC), Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M (2020)
   The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
   Sci Rep, 10 (1), 1277
   DOI 10.1038/s41598-020-57759-4, PubMed 31992741
8. Lavelle TJ, Alver TN, Heintz KM, Wernhoff P, Nygaard V, Nakken S, Øy GF, Bøe SL, Urbanucci A, Hovig E (2020)
   Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
   Cancers (Basel), 12 (7)
   DOI 10.3390/cancers12071719, PubMed 32605315
9. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Krauss S, Olberg DE, Waaler J, Klaveness J (2020)
   Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
   RSC Adv, 10 (9), 4927
   DOI 10.1039/d0ra90007a, PubMed 35503286
10. Pandya AD, Øverbye A, Sahariah P, Gaware VS, Høgset H, Masson M, Høgset A, Mælandsmo GM, Skotland T, Sandvig K, Iversen TG (2020)
    Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
    Biomacromolecules, 21 (4), 1489-1498
    DOI 10.1021/acs.biomac.0c00061, PubMed 32092254
11. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
    Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
    Acta Oncol, 59 (7), 733-740
    DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
12. Steinhaeuser SS, Morera E, Budkova Z, Schepsky A, Wang Q, Rolfsson O, Riedel A, Krueger A, Hilmarsdottir B, Maelandsmo GM, Valdimarsdottir B, Sigurdardottir AK, Agnarsson BA, Jonasson JG, Ingthorsson S, Traustadottir GA, Oskarsson T, Gudjonsson T (2020)
    ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
    Lab Invest, 100 (7), 928-944
    DOI 10.1038/s41374-020-0415-6, PubMed 32203150
13. Torgersen ML, Judge PJ, Bada Juarez JF, Pandya AD, Fusser M, Davies CW, Maciejewska MK, Yin DJ, Maelandsmo GM, Skotland T, Watts A, Sandvig K (2020)
    Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin
    J Biomed Nanotechnol, 16 (4), 419-431
    DOI 10.1166/jbn.2020.2911, PubMed 32970975

Publications 2019

1. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
   Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
   Acta Oncol, 59 (4), 404-409
   DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
2. Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
   O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
   Sci Rep, 9 (1), 5670
   DOI 10.1038/s41598-019-42153-6, PubMed 30952976
3. Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
   The β₂-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
   Mol Cancer Res, 17 (11), 2154-2168
   DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667
4. Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
   Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
   Breast Cancer Res, 21 (1), 9
   DOI 10.1186/s13058-018-1092-x, PubMed 30670061
5. Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
   Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
   J Proteome Res, 18 (10), 3649-3660
   DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
6. Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
   Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
   Mol Cancer Ther, 19 (3), 895-905
   DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
7. Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
   p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
   Sci Rep, 9 (1), 5839
   DOI 10.1038/s41598-019-42303-w, PubMed 30967582
8. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
   A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
   Transl Oncol, 12 (7), 951-958
   DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
9. Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
   Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
   Breast Cancer Res, 21 (1), 61
   DOI 10.1186/s13058-019-1141-0, PubMed 31088535
10. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
    Breast cancer quantitative proteome and proteogenomic landscape
    Nat Commun, 10 (1), 1600
    DOI 10.1038/s41467-019-09018-y, PubMed 30962452
11. Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2019)
    MX 2 is a novel regulator of cell cycle in melanoma cells
    Pigment Cell Melanoma Res, 33 (3), 446-457
    DOI 10.1111/pcmr.12837, PubMed 31660681
12. Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
    Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
    Cancer Res, 79 (16), 4293-4304
    DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
13. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
    Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
    RSC Adv, 9 (63), 37092-37100
    DOI 10.1039/c9ra08954c, PubMed 35539091
14. Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
    Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
    Arch Pharm (Weinheim), 352 (9), e1900101
    DOI 10.1002/ardp.201900101, PubMed 31414521
15. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol Oncol, 13 (10), 2278-2296
    DOI 10.1002/1878-0261.12561, PubMed 31402562
16. Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
    Int J Cancer, 146 (1), 223-235
    DOI 10.1002/ijc.32638, PubMed 31444972
17. Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
    Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
    Clin Exp Immunol, 197 (1), 74-82
    DOI 10.1111/cei.13283, PubMed 30821848
18. Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
    Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
    Int J Nanomedicine, 14, 6269-6285
    DOI 10.2147/IJN.S208938, PubMed 31496685
19. Pitman KE, Bakke KM, Kristian A, Malinen E (2019)
    Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist
    Cancer Imaging, 19 (1), 88
    DOI 10.1186/s40644-019-0280-y, PubMed 31856923
20. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
    Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
    Cancer Immunol Res, 7 (5), 701-706
    DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
21. Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
    Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
    Front Oncol, 9, 1302
    DOI 10.3389/fonc.2019.01302, PubMed 31921617

Publications 2018

1. Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
   Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
   BMC Cancer, 18 (1), 739
   DOI 10.1186/s12885-018-4659-0, PubMed 30005623
2. Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
   Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
   Br J Cancer, 118 (6), e11
   DOI 10.1038/bjc.2017.470, PubMed 29462127
3. Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK (2018)
   Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins
   Photochem Photobiol Sci, 17 (5), 539-551
   DOI 10.1039/C7PP00358G, PubMed 29565434
4. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
   Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
   J Control Release, 293, 183-192
   DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
5. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
   Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
   Mol Oncol, 12 (9), 1540-1558
   DOI 10.1002/1878-0261.12319, PubMed 29741811
6. Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW (2018)
   Role of serum response factor expression in prostate cancer biochemical recurrence
   Prostate, 78 (10), 724-730
   DOI 10.1002/pros.23516, PubMed 29608018
7. Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
   Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
   Cancer Lett, 439, 1-13
   DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

1. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
   Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
   Breast Cancer Res, 19 (1), 44
   DOI 10.1186/s13058-017-0812-y, PubMed 28356166
2. Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
   Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
   Br J Cancer, 117 (11), 1656-1664
   DOI 10.1038/bjc.2017.346, PubMed 28972967
3. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
   Interrogating open issues in cancer precision medicine with patient-derived xenografts
   Nat Rev Cancer, 17 (4), 254-268
   DOI 10.1038/nrc.2016.140, PubMed 28104906
4. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
   Interrogating open issues in cancer medicine with patient-derived xenografts
   Nat Rev Cancer, 17 (10), 632 (in press)
   DOI 10.1038/nrc.2017.85, PubMed 28912576
5. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
   Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
   Breast Cancer Res Treat, 162 (1), 127-137
   DOI 10.1007/s10549-016-4096-1, PubMed 28058579
6. Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
   Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
   Metabolomics, 13 (4), 37
   DOI 10.1007/s11306-017-1168-0
7. Halldorsson S, Rohatgi N, Magnusdottir M, Choudhary KS, Gudjonsson T, Knutsen E, Barkovskaya A, Hilmarsdottir B, Perander M, Mælandsmo GM, Gudmundsson S, Rolfsson Ó (2017)
   Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition
   Cancer Lett, 396, 117-129
   DOI 10.1016/j.canlet.2017.03.019, PubMed 28323032
8. Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Mælandsmo GM, Magnusson MK, Gudjonsson T (2017)
   Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells
   Cell Death Dis, 8 (5), e2769
   DOI 10.1038/cddis.2017.177, PubMed 28492548
9. Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
   Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
   Breast Cancer (Dove Med Press), 9, 185-198
   DOI 10.2147/BCTT.S115600, PubMed 28356768
10. Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
    Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
    Mol Imaging Biol, 19 (2), 271-279
    DOI 10.1007/s11307-016-0998-x, PubMed 27541026
11. Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R (2017)
    Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions
    Biochimie, 139, 27-37
    DOI 10.1016/j.biochi.2017.05.009, PubMed 28528272
12. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
13. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
    Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
    Mol Oncol, 11 (10), 1361-1379
    DOI 10.1002/1878-0261.12105, PubMed 28657165
14. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
    Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
    Oncotarget, 8 (44), 76290-76304
    DOI 10.18632/oncotarget.19350, PubMed 29100312
15. Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
    Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
    Oncotarget, 8 (44), 76921-76934
    DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

1. Alver TN, Lavelle TJ, Longva AS, Øy GF, Hovig E, Bøe SL (2016)
   MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma
   Oncotarget, 7 (34), 55128-55140
   DOI 10.18632/oncotarget.10422, PubMed 27391157
2. Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
   Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
   Cancer Med, 5 (8), 1840-9
   DOI 10.1002/cam4.766, PubMed 27273130
3. Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
   Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
   Oncotarget, 7 (2), 1878-94
   DOI 10.18632/oncotarget.6479, PubMed 26646591
4. Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
   Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
   Nature, 537 (7621), 548-552
   DOI 10.1038/nature19360, PubMed 27626377
5. Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
   Expression and clinical significance of Wee1 in colorectal cancer
   Tumour Biol, 37 (9), 12133-12140
   DOI 10.1007/s13277-016-5081-3, PubMed 27220319
6. Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fenaroli F, Hildahl J, Bagherifam S, Tulotta C, Prasmickaite L, Mælandsmo GM, Snaar-Jagalska E, Griffiths G (2016)
   Zebrafish as a model system for characterization of nanoparticles against cancer
   Nanoscale, 8 (2), 862-77
   DOI 10.1039/c5nr07289a, PubMed 26648525
7. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
   Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
   Clin Exp Metastasis, 34 (1), 51-62
   DOI 10.1007/s10585-016-9829-3, PubMed 27812769
8. Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
   hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
   Cell Death Discov, 2, 16081
   DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
9. Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
   The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
   PLoS One, 11 (12), e0167754
   DOI 10.1371/journal.pone.0167754, PubMed 28002446
10. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
    Br J Cancer, 115 (8), 929-939
    DOI 10.1038/bjc.2016.278, PubMed 27599042
11. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
    Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Cancer Res Treat, 49 (2), 374-386
    DOI 10.4143/crt.2016.080, PubMed 27488871
12. Kim E, Kim J, Maelandsmo GM, Johansen B, Moestue SA (2016)
    Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI
    Magn Reson Med, 78 (4), 1513-1522
    DOI 10.1002/mrm.26547, PubMed 27888545
13. Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
    Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
    BMC Cancer, 16, 191
    DOI 10.1186/s12885-016-2225-1, PubMed 26951085
14. Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F (2016)
    STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
    Oncotarget, 8 (54), 91817-91827
    DOI 10.18632/oncotarget.11131, PubMed 29190878
15. Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
    Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
    Urol Oncol, 35 (3), 111.e1-111.e8
    DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142
16. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
    Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
    Oncotarget, 7 (6), 6891-901
    DOI 10.18632/oncotarget.6902, PubMed 26771843
17. Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
    PBX3 is a putative biomarker of aggressive prostate cancer
    Int J Cancer, 139 (8), 1810-20
    DOI 10.1002/ijc.30220, PubMed 27273830
18. Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    Diagn Pathol, 11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
19. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
    Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Oncotarget, 7 (15), 19997-20015
    DOI 10.18632/oncotarget.7671, PubMed 26918352
20. Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
    Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
    PLoS One, 11 (10), e0165382
    DOI 10.1371/journal.pone.0165382, PubMed 27776176

Publications 2015

1. Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
   Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
   Gene Ther, 22 (5), 391-403
   DOI 10.1038/gt.2015.4, PubMed 25652098
2. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
   Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
   Br J Cancer, 113 (11), 1548-55
   DOI 10.1038/bjc.2015.380, PubMed 26554649
3. Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L (2015)
   Metabolic reprogramming supports the invasive phenotype in malignant melanoma
   Cancer Lett, 366 (1), 71-83
   DOI 10.1016/j.canlet.2015.06.006, PubMed 26095603
4. Braadland PR, Ramberg H, Grytli HH, Taskén KA (2015)
   β-Adrenergic Receptor Signaling in Prostate Cancer
   Front Oncol, 4, 375
   DOI 10.3389/fonc.2014.00375, PubMed 25629002
5. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
   Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
   Clin Exp Metastasis, 32 (8), 755-67
   DOI 10.1007/s10585-015-9742-1, PubMed 26349943
6. Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T (2015)
   HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
   Oncogene, 35 (32), 4244-55
   DOI 10.1038/onc.2015.489, PubMed 26686087
7. Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F (2015)
   STAMP2 increases oxidative stress and is critical for prostate cancer
   EMBO Mol Med, 7 (3), 315-31
   DOI 10.15252/emmm.201404181, PubMed 25680860
8. Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA (2015)
   Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
   BMC Cancer, 15, 462
   DOI 10.1186/s12885-015-1474-8, PubMed 26054341
9. Pitman KE, Rusten E, Kristian A, Malinen E (2015)
   Variability of dynamic 18F-FDG-PET data in breast cancer xenografts
   Acta Oncol, 54 (9), 1399-407
   DOI 10.3109/0284186X.2015.1062140, PubMed 26217987
10. Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
    Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
    Cancer Immunol Immunother, 64 (6), 769-76
    DOI 10.1007/s00262-015-1686-4, PubMed 25832001
11. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, Tsoporis JN, Kastania A, Filippopoulou A, Xiros N, Margaritis D, Parker TG, Papageorgiou C, Zoumpourlis V (2015)
    Correction: Let-7, Mir-98 and Mir-181 as Biomarkers for Cancer and Schizophrenia
    PLoS One, 10 (8), e0135863
    DOI 10.1371/journal.pone.0135863, PubMed 26266816
12. Skrbo N, Tenstad E, Mælandsmo GM, Sørlie T, Andersen K (2015)
    From autonomy to community; new perspectives on tumorigenicity and therapy resistance
    Cancer Treat Rev, 41 (10), 809-13
    DOI 10.1016/j.ctrv.2015.10.004, PubMed 26519005
13. Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
    Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
    Biochimie, 122, 208-18
    DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556
14. Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
    Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
    Data Brief, 5, 468-75
    DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

1. Bagherifam S, Griffiths GW, Mælandsmo GM, Nyström B, Hasirci V, Hasirci N (2014)
   Poly(sebacic anhydride) nanocapsules as carriers: effects of preparation parameters on properties and release of doxorubicin
   J Microencapsul, 32 (2), 166-74
   DOI 10.3109/02652048.2014.973073, PubMed 25323326
2. Bagherifam S, Skjeldal FM, Griffiths G, Mælandsmo GM, Engebråten O, Nyström B, Hasirci V, Hasirci N (2014)
   pH-responsive nano carriers for doxorubicin delivery
   Pharm Res, 32 (4), 1249-63
   DOI 10.1007/s11095-014-1530-0, PubMed 25288014
3. Brix K, McInnes J, Al-Hashimi A, Rehders M, Tamhane T, Haugen MH (2014)
   Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges
   Protoplasma, 252 (3), 755-74
   DOI 10.1007/s00709-014-0730-0, PubMed 25398648
4. Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2014)
   In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
   J Magn Reson Imaging, 41 (3), 601-9
   DOI 10.1002/jmri.24588, PubMed 24532410
5. Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
   Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
   Breast Cancer Res, 16 (1), R5
   DOI 10.1186/bcr3597, PubMed 24447408
6. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
   High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
   Eur J Cancer, 51 (1), 9-17
   DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
7. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014)
   Patient-derived xenograft models: an emerging platform for translational cancer research
   Cancer Discov, 4 (9), 998-1013
   DOI 10.1158/2159-8290.CD-14-0001, PubMed 25185190
8. Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
   Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
   Acta Oncol, 53 (8), 1086-92
   DOI 10.3109/0284186X.2014.934398, PubMed 25017377
9. Momtazi L, Bagherifam S, Singh G, Hofgaard A, Hakkarainen M, Glomm WR, Roos N, Mælandsmo GM, Griffiths G, Nyström B (2014)
   Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery
   J Colloid Interface Sci, 433, 76-85
   DOI 10.1016/j.jcis.2014.07.013, PubMed 25112915
10. Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
    Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
    J Magn Reson Imaging, 40 (6), 1382-91
    DOI 10.1002/jmri.24502, PubMed 24470360
11. Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E (2014)
    Melanoma brain colonization involves the emergence of a brain-adaptive phenotype
    Oncoscience, 1 (1), 82-94
    DOI 10.18632/oncoscience.11, PubMed 25593989
12. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
    Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
    J Enzyme Inhib Med Chem, 30 (5), 689-721
    DOI 10.3109/14756366.2014.966704, PubMed 25347767
13. Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
    Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
    PLoS One, 9 (11), e113278
    DOI 10.1371/journal.pone.0113278, PubMed 25419568
14. Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014)
    Generation and characterization of an immortalized human mesenchymal stromal cell line
    Stem Cells Dev, 23 (19), 2377-89
    DOI 10.1089/scd.2013.0599, PubMed 24857590

Publications 2013

1. Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L (2013)
   Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties
   Cancer Lett, 344 (1), 28-39
   DOI 10.1016/j.canlet.2013.10.036, PubMed 24215866
2. Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O (2013)
   Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts
   Anticancer Res, 33 (9), 3615-21
   PubMed 24023287
3. Engebraaten O, Vollan HKM, Børresen-Dale AL (2013)
   Triple-negative breast cancer and the need for new therapeutic targets
   Am J Pathol, 183 (4), 1064-1074
   DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
4. Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
   Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
   Magn Reson Med, 71 (6), 1973-81
   DOI 10.1002/mrm.24869, PubMed 23878023
5. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
   Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
   Int J Cancer, 133 (6), 1497-506
   DOI 10.1002/ijc.28158, PubMed 23494569
6. Friedman R, Boye K, Flatmark K (2013)
   Molecular modelling and simulations in cancer research
   Biochim Biophys Acta, 1836 (1), 1-14
   DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097
7. Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
   Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease
   Eur Urol, 65 (3), 635-41
   DOI 10.1016/j.eururo.2013.01.007, PubMed 23351721
8. Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
   Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007
   Eur Urol, 64 (1), e11-2
   DOI 10.1016/j.eururo.2013.03.045, PubMed 23602404
9. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
   Nuclear legumain activity in colorectal cancer
   PLoS One, 8 (1), e52980
   DOI 10.1371/journal.pone.0052980, PubMed 23326369
10. Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M (2013)
    High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
    PLoS One, 8 (10), e77232
    DOI 10.1371/journal.pone.0077232, PubMed 24194875
11. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
    O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
    Cancer Res, 73 (16), 5277-87
    DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054
12. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F (2013)
    Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer
    Proc Natl Acad Sci U S A, 110 (28), E2572-81
    DOI 10.1073/pnas.1304318110, PubMed 23798432
13. Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
    Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
    Nucl Med Mol Imaging, 47 (3), 173-80
    DOI 10.1007/s13139-013-0211-y, PubMed 24900104
14. Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
    Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
    Acta Oncol, 52 (7), 1566-72
    DOI 10.3109/0284186X.2013.813634, PubMed 23984812
15. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
    Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
    Clin Cancer Res, 20 (2), 404-12
    DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
16. Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
    Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
    Breast Cancer Res, 15 (1), R16
    DOI 10.1186/bcr3391, PubMed 23448424
17. Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
    Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
    J Magn Reson Imaging, 38 (5), 1043-53
    DOI 10.1002/jmri.24079, PubMed 23908122
18. Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T (2013)
    Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
    Acta Oncol, 52 (4), 776-82
    DOI 10.3109/0284186X.2013.770920, PubMed 23480638
19. Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
    Clinical significance of disseminated tumour cells in non-small cell lung cancer
    Br J Cancer, 109 (5), 1264-70
    DOI 10.1038/bjc.2013.450, PubMed 23942067
20. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
    Osteopontin is a prognostic biomarker in non-small cell lung cancer
    BMC Cancer, 13, 540
    DOI 10.1186/1471-2407-13-540, PubMed 24215488
21. Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
    Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
    J Surg Oncol, 109 (6), 521-6
    DOI 10.1002/jso.23527, PubMed 24347444
22. Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
    Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
    Carcinogenesis, 35 (1), 76-85
    DOI 10.1093/carcin/bgt333, PubMed 24104550

Publications 2012

1. Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
   Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
   Mol Oncol, 7 (1), 130-42
   DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
2. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
   EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
   Br J Cancer, 107 (4), 667-74
   DOI 10.1038/bjc.2012.293, PubMed 22782346
3. Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
   Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
   PLoS One, 7 (9), e45492
   DOI 10.1371/journal.pone.0045492, PubMed 23029050
4. Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL (2012)
   Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
   Prostate, 73 (3), 250-60
   DOI 10.1002/pros.22564, PubMed 22821802
5. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
   B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
   Int J Cancer, 131 (11), 2528-36
   DOI 10.1002/ijc.27566, PubMed 22473715
6. Kernstock S, Davydova E, Jakobsson M, Moen A, Pettersen S, Mælandsmo GM, Egge-Jacobsen W, Falnes PØ (2012)
   Lysine methylation of VCP by a member of a novel human protein methyltransferase family
   Nat Commun, 3, 1038
   DOI 10.1038/ncomms2041, PubMed 22948820
7. Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O (2012)
   Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
   Mol Oncol, 6 (4), 418-27
   DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242
8. Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA (2012)
   Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma
   Biochem Biophys Res Commun, 420 (3), 516-22
   DOI 10.1016/j.bbrc.2012.03.023, PubMed 22446330
9. Ree AH (2012)
   Individualised treatment of metastatic cancer
   Tidsskr Nor Laegeforen, 132 (21), 2358-9
   DOI 10.4045/tidsskr.12.1130, PubMed 23160572
10. Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K (2012)
    Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
    BMC Cancer, 12, 333
    DOI 10.1186/1471-2407-12-333, PubMed 22853000
11. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
    Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
    Radiat Oncol, 7, 165
    DOI 10.1186/1748-717X-7-165, PubMed 23017053
12. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
    Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
    BMC Cancer, 12, 505
    DOI 10.1186/1471-2407-12-505, PubMed 23121918
13. Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
    Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
    Tumor Biol., 33 (4), 1263-1264
    DOI 10.1007/s13277-012-0407-2
14. Selbo PK, Weyergang A, Eng MS, Bostad M, Mælandsmo GM, Høgset A, Berg K (2012)
    Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug
    J Control Release, 159 (2), 197-203
    DOI 10.1016/j.jconrel.2012.02.003, PubMed 22349185
15. Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
    Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
    BMC Cancer, 12, 73
    DOI 10.1186/1471-2407-12-73, PubMed 22356677
16. Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
    Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
    Cancer Biol Ther, 14 (2), 146-54
    DOI 10.4161/cbt.22953, PubMed 23192275
17. Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012)
    Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M
    Biochimie, 94 (12), 2590-9
    DOI 10.1016/j.biochi.2012.07.026, PubMed 22902879

Publications 2011

1. Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K, Mælandsmo GM (2011)
   Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis
   Int J Cancer, 129 (4), 780-90
   DOI 10.1002/ijc.25735, PubMed 20957651
2. Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø (2011)
   Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
   Int J Cancer, 129 (3), 742-50
   DOI 10.1002/ijc.25922, PubMed 21225632
3. Bøe S, Prasmickaite L, Engesæter B, Hovig E (2011)
   Light-directed delivery of nucleic acids
   Methods Mol Biol, 764, 107-21
   DOI 10.1007/978-1-61779-188-8_7, PubMed 21748636
4. Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
   Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
   Cancer Biol Ther, 12 (1), 47-58
   DOI 10.4161/cbt.12.1.15714, PubMed 21508672
5. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
   Disseminated tumour cells as a prognostic biomarker in colorectal cancer
   Br J Cancer, 104 (9), 1434-9
   DOI 10.1038/bjc.2011.97, PubMed 21448171
6. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2011)
   In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
   J Magn Reson Imaging, 35 (5), 1098-107
   DOI 10.1002/jmri.23507, PubMed 22170753
7. Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M (2011)
   B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation
   Mol Cancer Ther, 10 (6), 960-71
   DOI 10.1158/1535-7163.MCT-11-0072, PubMed 21518725
8. Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
   Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
   J Immunother, 34 (5), 438-47
   DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141
9. Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
   Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
   Tumour Biol, 33 (1), 73-83
   DOI 10.1007/s13277-011-0247-5, PubMed 22006279
10. Tveito S, Andersen K, Kåresen R, Fodstad Ø (2011)
    Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles
    Breast Cancer Res, 13 (4), R75
    DOI 10.1186/bcr2922, PubMed 21816090

Publications 2010

1. Andersen K, Mori H, Fata J, Bascom J, Oyjord T, Mælandsmo GM, Bissell M (2010)
   The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis
   Dev Biol, 352 (2), 181-90
   DOI 10.1016/j.ydbio.2010.12.033, PubMed 21195708
2. Berg K, Weyergang A, Prasmickaite L, Bonsted A, Høgset A, Strand MT, Wagner E, Selbo PK (2010)
   Photochemical internalization (PCI): a technology for drug delivery
   Methods Mol Biol, 635, 133-45
   DOI 10.1007/978-1-60761-697-9_10, PubMed 20552345
3. Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
   Comment on the Importance of S100A4 in regulation of MMP-13
   J Biol Chem, 285 (53), le23; author reply le24
   DOI 10.1074/jbc.L110.125898, PubMed 21186294
4. Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
   Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
   Amino Acids, 41 (4), 875-84
   DOI 10.1007/s00726-010-0514-6, PubMed 20191297
5. Berge G, Mælandsmo GM (2010)
   Evaluation of potential interactions between the metastasis-associated protein S100A4 and the tumor suppressor protein p53
   Amino Acids, 41 (4), 863-73
   DOI 10.1007/s00726-010-0497-3, PubMed 20177948
6. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
   Nuclear S100A4 is a novel prognostic marker in colorectal cancer
   Eur J Cancer, 46 (16), 2919-25
   DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498
7. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
   Cystatin E/M suppresses legumain activity and invasion of human melanoma
   BMC Cancer, 10, 17
   DOI 10.1186/1471-2407-10-17, PubMed 20074384
8. Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
   Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
   Hum Pathol, 41 (8), 1109-19
   DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
9. Grotterød I, Maelandsmo GM, Boye K (2010)
   Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB
   BMC Cancer, 10, 241
   DOI 10.1186/1471-2407-10-241, PubMed 20507646
10. Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F (2010)
    PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells
    Cell Oncol, 32 (1-2), 11-27
    DOI 10.3233/CLO-2009-0487, PubMed 20203370
11. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS (2010)
    Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
    BMC Cancer, 10, 433
    DOI 10.1186/1471-2407-10-433, PubMed 20716336
12. Olberg DE, Cuthbertson A, Solbakken M, Arukwe JM, Qu H, Kristian A, Bruheim S, Hjelstuen OK (2010)
    Radiosynthesis and biodistribution of a prosthetic group (¹⁸F-FENMA) conjugated to cyclic RGD peptides
    Bioconjug Chem, 21 (12), 2297-304
    DOI 10.1021/bc1003229, PubMed 21070000
13. Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
    Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
    Int J Cancer, 126 (2), 350-61
    DOI 10.1002/ijc.24727, PubMed 19588500
14. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
    TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
    Tumour Biol, 32 (1), 1-12
    DOI 10.1007/s13277-010-0073-1, PubMed 20652782
15. Prasmickaite L, Engesaeter BØ, Skrbo N, Hellenes T, Kristian A, Oliver NK, Suo Z, Maelandsmo GM (2010)
    Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma
    PLoS One, 5 (5), e10731
    DOI 10.1371/journal.pone.0010731, PubMed 20505780
16. Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
    Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
    Pigment Cell Melanoma Res, 23 (3), 449-51
    DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249
17. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
    Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
    Lancet Oncol, 11 (5), 459-64
    DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407
18. Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E (2010)
    Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis
    Acta Oncol, 49 (7), 914-21
    DOI 10.3109/0284186X.2010.498831, PubMed 20831478
19. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR (2010)
    Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
    Neoplasia, 12 (10), 818-25
    DOI 10.1593/neo.10484, PubMed 20927320
20. Solberg R, Andresen JH, Pettersen S, Wright MS, Munkeby BH, Charrat E, Khrestchatisky M, Rivera S, Saugstad OD (2010)
    Resuscitation of hypoxic newborn piglets with supplementary oxygen induces dose-dependent increase in matrix metalloproteinase-activity and down-regulates vital genes
    Pediatr Res, 67 (3), 250-6
    DOI 10.1203/PDR.0b013e3181cde843, PubMed 20010314
21. Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F (2010)
    STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer
    Cancer Res, 70 (14), 5818-28
    DOI 10.1158/0008-5472.CAN-09-4697, PubMed 20587517
22. Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y (2010)
    A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
    Cancer Immunol Immunother, 59 (11), 1665-74
    DOI 10.1007/s00262-010-0892-3, PubMed 20635083

Publications 2009

1. Andersson Y, Engebraaten O, Fodstad Ø (2009)
   Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
   Br J Cancer, 101 (8), 1307-15
   DOI 10.1038/sj.bjc.6605312, PubMed 19773757
2. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
   Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
   Mol Oncol, 3 (5-6), 469-82
   DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
3. Boye K, Maelandsmo GM (2009)
   S100A4 and metastasis: a small actor playing many roles
   Am J Pathol, 176 (2), 528-35
   DOI 10.2353/ajpath.2010.090526, PubMed 20019188
4. Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
   Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
   Clin Exp Metastasis, 26 (5), 485-96
   DOI 10.1007/s10585-009-9248-9, PubMed 19294521
5. Cedervall J, Jamil S, Prasmickaite L, Cheng Y, Eskandarpour M, Hansson J, Maelandsmo GM, Ringborg U, Gulyas M, Zhen HS, Kanter L, Ahrlund-Richter L (2009)
   Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts
   Cancer Res, 69 (9), 3746-54
   DOI 10.1158/0008-5472.CAN-08-3746, PubMed 19383913
6. Elenjord R, Allen JB, Johansen HT, Kildalsen H, Svineng G, Maelandsmo GM, Loennechen T, Winberg JO (2009)
   Collagen I regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent of S100A4
   FEBS J, 276 (18), 5275-86
   DOI 10.1111/j.1742-4658.2009.07223.x, PubMed 19682073
7. Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø (2009)
   Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
   Anticancer Res, 29 (1), 131-7
   PubMed 19331142
8. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
   Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
   Int J Radiat Oncol Biol Phys, 74 (2), 546-52
   DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556
9. Hoyem S, Bruheim S, Maelandsmo G, Standal M, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
   Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats (vol 44, pg 3874, 2009)
   Eur. J. Med. Chem., 44 (11), 4786
   DOI 10.1016/j.ejmech.2009.08.006
10. Høyem S, Bruheim S, Maelandsmo G, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
    Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats
    Eur J Med Chem, 44 (10), 3874-9
    DOI 10.1016/j.ejmech.2009.04.008, PubMed 19433342
11. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
    Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
    Tumour Biol, 30 (1), 15-25
    DOI 10.1159/000199447, PubMed 19194111
12. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
    MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
    Radiother Oncol, 93 (2), 279-84
    DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704
13. Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
    Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
    Hum Pathol, 40 (4), 527-37
    DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847

Publications 2008

1. Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F (2008)
   The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer
   Cancer Res, 68 (22), 9255-64
   DOI 10.1158/0008-5472.CAN-08-1224, PubMed 19010898
2. Bonsted A, Wagner E, Prasmickaite L, Høgset A, Berg K (2008)
   Photochemical enhancement of DNA delivery by EGF receptor targeted polyplexes
   Methods Mol Biol, 434, 171-81
   DOI 10.1007/978-1-60327-248-3_11, PubMed 18470645
3. Boye K, Grotterød I, Aasheim HC, Hovig E, Maelandsmo GM (2008)
   Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes
   Int J Cancer, 123 (6), 1301-10
   DOI 10.1002/ijc.23617, PubMed 18548584
4. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
   The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
   BMC Cancer, 8, 172
   DOI 10.1186/1471-2407-8-172, PubMed 18554396
5. Ree AH (2008)
   Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response
   Radiat Oncol, 3, 13
   DOI 10.1186/1748-717X-3-13, PubMed 18489745
6. Ree AH, Bratland A, Dueland S (2008)
   [Molecular targeted therapy in colorectal cancer]
   Tidsskr Nor Laegeforen, 128 (2), 190-3
   PubMed 18202731
7. Ree AH, Folkvord S, Flatmark K (2008)
   HDAC2 deficiency and histone acetylation
   Nat Genet, 40 (7), 812-3; author reply 813
   DOI 10.1038/ng0708-812, PubMed 18583969
8. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
   Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
   Mol Cancer, 7, 33
   DOI 10.1186/1476-4598-7-33, PubMed 18439252

Publications 2007

1. Berg K, Folini M, Prasmickaite L, Selbo PK, Bonsted A, Engesaeter BØ, Zaffaroni N, Weyergang A, Dietze A, Maelandsmo GM, Wagner E, Norum OJ, Høgset A (2007)
   Photochemical internalization: a new tool for drug delivery
   Curr Pharm Biotechnol, 8 (6), 362-72
   DOI 10.2174/138920107783018354, PubMed 18289045
2. Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N (2007)
   Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer
   Int J Cancer, 121 (7), 1433-44
   DOI 10.1002/ijc.22850, PubMed 17565747
3. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
   Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
   Radiother Oncol, 86 (3), 428-34
   DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097
4. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
   Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
   J Gene Med, 9 (6), 440-51
   DOI 10.1002/jgm.1036, PubMed 17410615
5. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
   Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
   Eur J Gynaecol Oncol, 28 (5), 356-63
   PubMed 17966213
6. Rafferty M, Faller WJ, Moss C, McCormack J, Mãlandsmo GM, Easty DJ, Gallagher WM (2007)
   Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes
   Anticancer Res, 27 (3A), 1301-7
   PubMed 17593623
7. Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodstad O (2007)
   Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
   Clin Exp Metastasis, 24 (5), 317-27
   DOI 10.1007/s10585-006-9052-8, PubMed 17530423

Publications 2006

1. Andersson Y, Le H, Juell S, Fodstad Ø (2006)
   AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death
   Mol Cancer Ther, 5 (4), 1050-9
   DOI 10.1158/1535-7163.MCT-05-0318, PubMed 16648577
2. Bonsted A, Engesaeter BØ, Høgset A, Berg K (2006)
   Photochemically enhanced adenoviral transduction in a multicellular environment
   Photochem Photobiol Sci, 5 (4), 411-21
   DOI 10.1039/b515066c, PubMed 16583022
3. Bonsted A, Engesaeter BØ, Høgset A, Maelandsmo GM, Prasmickaite L, D'Oliveira C, Hennink WE, van Steenis JH, Berg K (2006)
   Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor
   J Gene Med, 8 (3), 286-97
   DOI 10.1002/jgm.853, PubMed 16342300
4. Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
   Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
   Tumour Biol, 28 (1), 27-35
   DOI 10.1159/000097700, PubMed 17143014
5. Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
   Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
   BMC Cardiovasc Disord, 6, 40
   DOI 10.1186/1471-2261-6-40, PubMed 17029634
6. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA (2006)
   The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes
   Genes Chromosomes Cancer, 45 (1), 31-41
   DOI 10.1002/gcc.20261, PubMed 16145679
7. Dietze A, Selbo PK, Prasmickaite L, Weyergang A, Bonsted A, Engesaeter B, Hogset A, Berg K (2006)
   Photochemical internalization (PCI): a new modality for light activation of endocytosed therapeuticals
   J Environ Pathol Toxicol Oncol, 25 (1-2), 521-36
   DOI 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.330, PubMed 16566739
8. Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM (2006)
   Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
   Cancer Biol Ther, 5 (11), 1511-20
   DOI 10.4161/cbt.5.11.3301, PubMed 17012835
9. Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
   Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
   J Gene Med, 8 (6), 707-18
   DOI 10.1002/jgm.902, PubMed 16518880
10. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
    Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
    Radiat Oncol, 1, 25
    DOI 10.1186/1748-717X-1-25, PubMed 16887021
11. Frich L, Bjørnland K, Pettersen S, Clausen OP, Gladhaug IP (2006)
    Increased activity of matrix metalloproteinase 2 and 9 after hepatic radiofrequency ablation
    J Surg Res, 135 (2), 297-304
    DOI 10.1016/j.jss.2006.05.010, PubMed 16934296
12. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
    ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
    Cell Oncol, 28 (5-6), 259-72
    DOI 10.1155/2006/949506, PubMed 17167179
13. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
    ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
    Cell. Oncol., 28 (5-6), 259-272
14. Ree AH (2006)
    A complex case of rectal neuroendocrine carcinoma with terminal delirium
    Nat Clin Pract Gastroenterol Hepatol, 3 (7), 408-13; quiz 414
    DOI 10.1038/ncpgasthep0525, PubMed 16819503
15. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
    DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
    Anticancer Res, 26 (3A), 1909-16
    PubMed 16827124

Publications 2005

1. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BØ, Angell-Petersen E, Warloe T, Frandsen N, Høgset A (2005)
   Porphyrin-related photosensitizers for cancer imaging and therapeutic applications
   J Microsc, 218 (Pt 2), 133-47
   DOI 10.1111/j.1365-2818.2005.01471.x, PubMed 15857375
2. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
   Matrix metalloproteinases participate in osteosarcoma invasion
   J Surg Res, 127 (2), 151-6
   DOI 10.1016/j.jss.2004.12.016, PubMed 16083752
3. Dietze A, Engesaeter B, Berg K (2005)
   Transgene delivery and gelonin cytotoxicity enhanced by photochemical internalization in fibroblast-like synoviocytes (FLS) from rheumatoid arthritis patients
   Photochem Photobiol Sci, 4 (4), 341-7
   DOI 10.1039/b416521g, PubMed 15803204
4. Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
   PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
   Cancer Gene Ther, 12 (5), 439-48
   DOI 10.1038/sj.cgt.7700808, PubMed 15678152
5. Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
   Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
   Cancer Gene Ther, 12 (11), 864-72
   DOI 10.1038/sj.cgt.7700852, PubMed 15891771
6. Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
   Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
   Int J Cancer, 115 (6), 935-42
   DOI 10.1002/ijc.20962, PubMed 15723354
7. Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL, Parks RJ (2005)
   Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice
   J Gene Med, 7 (3), 307-15
   DOI 10.1002/jgm.666, PubMed 15515146
8. McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty DJ (2005)
   Microarray analysis of phosphatase gene expression in human melanoma
   Br J Dermatol, 152 (5), 925-30
   DOI 10.1111/j.1365-2133.2005.06454.x, PubMed 15888148
9. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
   Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
   Mol Cancer Ther, 4 (8), 1231-8
   DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439
10. Porojnicu AC, Robsahm TE, Ree AH, Moan J (2005)
    Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D
    Br J Cancer, 93 (5), 571-4
    DOI 10.1038/sj.bjc.6602722, PubMed 16136030

Publications 2004

1. Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
   Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
   Mod Pathol, 17 (8), 990-7
   DOI 10.1038/modpathol.3800151, PubMed 15133476
2. Andersson Y, Juell S, Fodstad Ø (2004)
   Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin
   Int J Cancer, 112 (3), 475-83
   DOI 10.1002/ijc.20371, PubMed 15382075
3. Berg K, Selbo PK, Prasmickaite L, Høgset A (2004)
   Photochemical drug and gene delivery
   Curr Opin Mol Ther, 6 (3), 279-87
   PubMed 15264430
4. Bonsted A, Engesaeter BØ, Høgset A, Maelandsmo GM, Prasmickaite L, Kaalhus O, Berg K (2004)
   Transgene expression is increased by photochemically mediated transduction of polycation-complexed adenoviruses
   Gene Ther, 11 (2), 152-60
   DOI 10.1038/sj.gt.3302166, PubMed 14712299
5. Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O (2004)
   Human osteosarcoma xenografts and their sensitivity to chemotherapy
   Pathol Oncol Res, 10 (3), 133-41
   DOI 10.1007/BF03033741, PubMed 15448748
6. DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA (2004)
   Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
   J Steroid Biochem Mol Biol, 92 (5), 365-74
   DOI 10.1016/j.jsbmb.2004.07.011, PubMed 15698541
7. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
   Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
   Eur J Cancer, 40 (10), 1593-8
   DOI 10.1016/j.ejca.2004.02.023, PubMed 15196545
8. Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
   Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
   Tumour Biol, 25 (1-2), 31-40
   DOI 10.1159/000077721, PubMed 15192310
9. Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
   Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
   Am J Clin Pathol, 122 (3), 412-20
   DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372
10. Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O (2004)
    Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
    J Neurosurg, 100 (2), 320-7
    DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240
11. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O (2004)
    Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
    Exp Cell Res, 294 (1), 130-9
    DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508
12. Høgset A, Prasmickaite L, Selbo PK, Hellum M, Engesaeter BØ, Bonsted A, Berg K (2004)
    Photochemical internalisation in drug and gene delivery
    Adv Drug Deliv Rev, 56 (1), 95-115
    DOI 10.1016/j.addr.2003.08.016, PubMed 14706447
13. Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Taskén K (2004)
    The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types
    Endocrinology, 145 (11), 5177-84
    DOI 10.1210/en.2004-0232, PubMed 15284208
14. Kloeckner J, Prasmickaite L, Høgset A, Berg K, Wagner E (2004)
    Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes
    J Drug Target, 12 (4), 205-13
    DOI 10.1080/10611860410001723090, PubMed 15506169
15. Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T, Clark SA, Ross PJ, Meulenbroek RA, Maelandsmo GM, Parks RJ (2004)
    Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo
    J Virol, 78 (11), 5966-72
    DOI 10.1128/JVI.78.11.5966-5972.2004, PubMed 15140994
16. Pedersen KB, Andersen K, Fodstad Ø, Maelandsmo GM (2004)
    Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4
    BMC Cancer, 4, 52
    DOI 10.1186/1471-2407-4-52, PubMed 15318945
17. Prasmickaite L, Høgset A, Olsen VM, Kaalhus O, Mikalsen SO, Berg K (2004)
    Photochemically enhanced gene transfection increases the cytotoxicity of the herpes simplex virus thymidine kinase gene combined with ganciclovir
    Cancer Gene Ther, 11 (7), 514-23
    DOI 10.1038/sj.cgt.7700720, PubMed 15118758
18. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
    Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
    Radiother Oncol, 72 (3), 305-10
    DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729
19. Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
    Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
    Anticancer Res, 24 (2B), 555-62
    PubMed 15160994
20. Wang JE, Pettersen S, Stuestol JF, Wang YY, Foster SJ, Thiemermann C, Aasen AO, Bjørnland K (2004)
    Peptidoglycan of S. aureus causes increased levels of matrix metalloproteinases in the rat
    Shock, 22 (4), 376-9
    DOI 10.1097/01.shk.0000140299.48063.89, PubMed 15377895